UK's Bicycle Therapeutics Q4 revenue jumps, proposes 30% workforce reduction

Bicycle Therapeutics

17/03/2026 11:19

Overview

UK pharmaceutical developer reported Q4 collaboration revenue surged yr/yr due to terminated partnerships

Company posted Q4 net loss as R&D expenses rose from clinical program and severance costs

Strategic reprioritization includes proposed 30% workforce reduction and discontinuation of several clinical trials

Outlook

Company expects cash runway to extend into 2030 following strategic reprioritization and cost reductions

Result Drivers

COLLABORATION REVENUE - Q4 collaboration revenue rose sharply due to recognition of remaining revenue from terminated Novartis and Bayer partnerships

R&D EXPENSES - Higher R&D costs driven by zelenectide development, discovery activities, and severance from workforce reduction

STRATEGIC REPRIORITIZATION - Company is discontinuing several trials and reducing workforce to focus on next-generation pipeline and extend cash runway

Company press release: ID:nBw9Hww6wa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$20.15 mln
Q4 Basic EPS
-$0.29
Q4 Operating Expenses
$72.66 mln
Q4 Operating Incom
-$24.71 mln
Q4 Pretax Profit
-$18.89 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $14.00, about 177.2% above its March 16 closing price of $5.05

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)